Dr Markus Anker
- Honorary Research Fellow (School of Cardiovascular & Metabolic Health)
The University of Glasgow uses cookies for analytics. Find out more about our Privacy policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.
Analytical cookies help us improve our website. We use Google Analytics. All data is anonymised.
Clarity helps us to understand our users’ behaviour by visually representing their clicks, taps and scrolling. All data is anonymised.
Keramida, K. et al. (2025) Heart failure with preserved ejection fraction in cancer patients and survivors. A scientific statement of the Heart Failure Association of the ESC and the ESC Council of Cardio‐Oncology. European Journal of Heart Failure, (doi: 10.1002/ejhf.70005) (PMID:40938778) (Early Online Publication)
Anker, M. S. et al. (2025) Randomized investigation of heart failure therapy in patients with advanced cancer at risk of cardiac wasting: rationale and design of the EMPATICC trial. European Journal of Heart Failure, (doi: 10.1002/ejhf.3799) (PMID:40857084) (Early Online Publication)
Anker, M. S. et al. (2025) Clinical and echocardiographic phenotype of cardiac wasting in patients with advanced cancer. European Journal of Heart Failure, (doi: 10.1002/ejhf.3744) (PMID:40767389) (Early Online Publication)
Anker, S. D. et al. (2025) Ferric carboxymaltose assessment of morbidity and mortality in patients with iron deficiency and chronic heart failure ( FAIR ‐ HF2 ‐ DZHK05 ) trial: baseline characteristics and comparison to other relevant clinical trials. European Journal of Heart Failure, 27(8), pp. 1436-1443. (doi: 10.1002/ejhf.3658) (PMID:40300786) (PMCID:PMC12482851)
Stolfo, D. et al. (2025) How to handle polypharmacy in heart failure. A clinical consensus statement of the Heart Failure Association of the ESC. European Journal of Heart Failure, 27(5), pp. 747-759. (doi: 10.1002/ejhf.3642) (PMID:40091554) (PMCID:PMC12103960)
Keramida, K. et al. (2025) Heart failure with preserved ejection fraction in cancer patients and survivors. A scientific statement of the Heart Failure Association of the ESC and the ESC Council of Cardio‐Oncology. European Journal of Heart Failure, (doi: 10.1002/ejhf.70005) (PMID:40938778) (Early Online Publication)
Anker, M. S. et al. (2025) Randomized investigation of heart failure therapy in patients with advanced cancer at risk of cardiac wasting: rationale and design of the EMPATICC trial. European Journal of Heart Failure, (doi: 10.1002/ejhf.3799) (PMID:40857084) (Early Online Publication)
Anker, M. S. et al. (2025) Clinical and echocardiographic phenotype of cardiac wasting in patients with advanced cancer. European Journal of Heart Failure, (doi: 10.1002/ejhf.3744) (PMID:40767389) (Early Online Publication)
Anker, S. D. et al. (2025) Ferric carboxymaltose assessment of morbidity and mortality in patients with iron deficiency and chronic heart failure ( FAIR ‐ HF2 ‐ DZHK05 ) trial: baseline characteristics and comparison to other relevant clinical trials. European Journal of Heart Failure, 27(8), pp. 1436-1443. (doi: 10.1002/ejhf.3658) (PMID:40300786) (PMCID:PMC12482851)
Stolfo, D. et al. (2025) How to handle polypharmacy in heart failure. A clinical consensus statement of the Heart Failure Association of the ESC. European Journal of Heart Failure, 27(5), pp. 747-759. (doi: 10.1002/ejhf.3642) (PMID:40091554) (PMCID:PMC12103960)